Results 61 to 70 of about 3,679,356 (272)

Myelodysplastic syndromes: Where do we stand?

Asian Journal of Oncology, 2016
Myelodysplastic syndromes (MDS) are fairly common hematological disorder of elderly. They are a group of clonal malignant hematopoietic stem cell disorders characterized by dysplastic morphology, variable cytopenia and a variable threat of transformation
Nitin Sood, Bhuvan Chugh, Esha Singhal, Ritesh Sachdev, Shalini Goel, Gajendra Smeeta   +5 more
doaj   +1 more source

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes

iScience, 2022
Summary Hypomethylating agents (HMA) prolong survival and improve cytopenias in individuals with higher-risk myelodysplastic syndrome (MDS). Only 30-40% of patients, however, respond to HMAs, and responses may not occur for more than 6 months after HMA ...
N. Radakovich, D. Sallman, R. Buckstein, A. Brunner, A. Dezern, Sudipto Mukerjee, R. Komrokji, Najla Al-Ali, Jacob Shreve, Yazan Rouphail, A. Parmentier, A. Mamedov, M. Siddiqui, Y. Guan, T. Kuzmanovic, M. Hasipek, B. Jha, J. Maciejewski, M. Sekeres, A. Nazha   +19 more
semanticscholar   +1 more source

Epigenetic targeting of ovarian cancer stem cells [PDF]

, 2014
Emerging results indicate that cancer stem-like cells contribute to chemoresistance and poor clinical outcomes in many cancers, including ovarian cancer.
Cardenas, Horacio, Condello, Salvatore, Fang, Fang, Liu, Yunlong, Matei, Daniela, Nephew, Kenneth P., Segar, Matthew, Taverna, Pietro, Wang, Yinu   +8 more
core   +2 more sources

Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study

Leukemia and Lymphoma, 2022
The phase 1b multicohort KEYNOTE-013 study assessed the safety and antitumor activity of pembrolizumab given at 10 mg/kg/day every 2 weeks for up to 2 years in hematologic malignancies, including myelodysplastic syndromes (MDS) refractory to a ...
G. Garcia-Manero, V. Ribrag, Yayan Zhang, M. Farooqui, P. Marinello, B. Smith   +5 more
semanticscholar   +1 more source

Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma [PDF]

, 2016
Hepatocellular carcinoma (HCC) is a deadly malignancy characterized at the epigenetic level by global DNA hypomethylation and focal hypermethylation on the promoter of tumor suppressor genes.
Azab, M., Cannito, S., CAPPELLO, Francesco, Jueliger, S., Lo Re, O., Lyons, J., Pata, I., Pata, P., Pazienza, V., Peyrou, M., RAPPA, Francesca, Shkolnaya, M., Taverna, P., Villarroya, F., Vinciguerra, M.   +14 more
core   +2 more sources

Low-dose hypomethylating agents cooperate with ferroptosis inducers to enhance ferroptosis by regulating the DNA methylation-mediated MAGEA6-AMPK-SLC7A11-GPX4 signaling pathway in acute myeloid leukemia

Experimental Hematology & Oncology
Background Ferroptosis is a new form of nonapoptotic and iron-dependent type of cell death. Glutathione peroxidase-4 (GPX4) plays an essential role in anti-ferroptosis by reducing lipid peroxidation.
Shuya Feng, Yigang Yuan, Zihan Lin, Min Li, Daijiao Ye, Liuzhi Shi, Danyang Li, Min Zhao, Chen Meng, Xiaofei He, Shanshan Wu, Fang Xiong, Siyu Ye, Junjun Yang, Haifeng Zhuang, Lili Hong, Shenmeng Gao   +16 more
semanticscholar   +1 more source

Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis

Frontiers in Medicine, 2021
Introduction Hypomethylating agents (HMAs) seem to have a range of properties favorable to post-allogeneic hematopoietic stem cell transplantation (allo-SCT) maintenance in acute myeloid leukemia (AML) patients. Materials and Methods The Embase, MEDLINE,
S. Kungwankiattichai, B. Ponvilawan, C. Roy, Pattaraporn Tunsing, F. Kuchenbauer, W. Owattanapanich   +5 more
semanticscholar   +1 more source

Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients

Leukemia
The clinical impact of molecular ontogeny in acute myeloid leukemia (AML) was defined in patients treated with intensive chemotherapy. In a cohort of 314 newly diagnosed AML patients, we evaluated whether molecular ontogeny subgroups have differential ...
S. Shimony, Jacqueline S. Garcia, Julia H. Keating, Evan C Chen, M. Luskin, Maximilian F. Stahl, D. Neuberg, D. DeAngelo, Richard M. Stone, R. C. Lindsley   +9 more
semanticscholar   +1 more source

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter

Frontiers in Oncology, 2021
Abnormal DNA methylation patterns are thought to drive the pathobiology of high-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukemia (AML).
C. Kordella, E. Lamprianidou, I. Kotsianidis   +2 more
semanticscholar   +1 more source

Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review

Journal of Oncology Pharmacy Practice
Objective To review the pharmacokinetic (PK)–pharmacodynamic (PD) profiles, disease setting, dosing, and safety of oral and parenteral hypomethylating agents (HMAs) for the treatment of myelodysplastic syndromes/neoplasms (MDS) and acute myeloid leukemia
Ryan Haumschild, Julie Kennerly-Shah, Lisa Barbarotta, A. Zeidan   +3 more
semanticscholar   +1 more source